Healthcare / Medical DevicesKOSDAQ
$2915.00
-65.00 (-2.18%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 21%
FCF escenarios
weak_data · normalized FCF $-8.8B · quality 59.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
19/100
F
Piotroski
1/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$53.1B
P/E
N/A
•EV/EBITDA
N/A
•ROE
-45.4%
↓Gross Margin
28.3%
↓Debt/Equity
0.80
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+13.1%
FCF CAGR
—
FCF margin
-105.1%
FCF / Net income
1.03x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $12.84B · net income $-13.15B · FCF $-13.50B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $12.84B | $12.84B | $11.53B | $10.84B | $8.88B |
| Net Income | $-13.15B | $-13.15B | $449.6M | $590.1M | $-9.34B |
| EBITDA | $-9.48B | $-9.48B | $3.72B | $3.93B | $-6.27B |
| EPS | — | — | -7.00 | 38.00 | -596.00 |
| Gross Margin | 28.3% | 28.3% | 53.7% | 56.9% | 2.6% |
| Operating Margin | -71.4% | -71.4% | 2.4% | 8.1% | -89.5% |
| Net Margin | -102.4% | -102.4% | 3.9% | 5.4% | -105.1% |
| Balance Sheet | |||||
| Debt/Equity | 0.80 | 0.80 | 0.54 | 1.58 | 2.61 |
| Current Ratio | 2.36 | 2.36 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-13.50B | $-13.50B | $-8.83B | $-5.62B | $-8.27B |
| Returns | |||||
| ROE | -45.4% | -45.4% | 1.5% | 6.8% | -171.7% |
| Valuation | |||||
| P/E | — | — | — | 173.16 | — |
| EV/EBITDA | — | — | 50.00 | 29.24 | — |
| P/B | 1.83 | 1.83 | 6.28 | 11.72 | 10.20 |
| Growth & Yield | |||||
| Revenue Growth | 11.4% | 11.4% | 6.4% | 22.0% | — |
| EPS Growth | — | — | -118.4% | 106.4% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-67.0%
Start / end P/E
n/dx → n/dx
EPS bridge
-7.00 → n/d
Residual
-67.0%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.